



Erratum

Cite this article: Kaski JP, Kammeraad JAE, Blom NA, Happonen J-M, Janousek J, Klaassen S, Limongelli G, Östman-Smith I, Sarquella Brugada G, and Ziolkowska L (2024) Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy: A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology – ERRATUM. *Cardiology in the Young* **34**: 469. doi: [10.1017/S1047951123004237](https://doi.org/10.1017/S1047951123004237)

First published online: 22 January 2024

Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy: A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology – ERRATUM

Juan Pablo Kaski, Janneke A.E. Kammeraad, Nico A. Blom, Juha-Matti Happonen, Jan Janousek, Sabine Klaassen, Giuseppe Limongelli, Ingegerd Östman-Smith, Georgia Sarquella Brugada and Lidia Ziolkowska

Doi: <https://doi.org/10.1017/S1047951123000872>, published online by Cambridge University Press, 27 April 2023.

The publisher apologises that the final three pages of this article were missing in its initial publication. This article has been updated to include the pages.

Reference

Kaski JP, Kammeraad JAE, Blom NA, et al. Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy: A position statement from the AEPC Working Group on Basic Science, Genetics and Myocardial Disease and the AEPC Working Group on Cardiac Dysrhythmias and Electrophysiology. *Cardiology in the Young*. 2023;33(5):681–698. doi: [10.1017/S1047951123000872](https://doi.org/10.1017/S1047951123000872)